SUBMIT MEDICAL INFORMATION REQUEST
Can’t find the information you are looking for? Would you like a copy of the full-text publication?
This site is intended for US Healthcare Professionals only
Publications
Gastroenterology
Filters
Safety and efficacy of fecal microbiota, live-jslm (REBYOTA®) for the prevention of recurrence C. difficile infection in participants with inflammatory bowel disease ...
Allegretti J, Feuerstadt P, Knapple WL, Orenstein R, Sheh A, Khanna S.
2024
Inflammatory Bowel Diseases (in Press)
Microbiome and Metabolome Restoration After Administration of Fecal Microbiota, Live-jslm (REBYOTA®) for Preventing Recurrent Clostridioides difficile Infection.
Blount K, Papazyan R, Ferdyan N, Srinivasan K, Gonzales C, Shannon W, Fuchs BC.
2024
Journal of Infectious Diseases
Fecal Microbiota, Live-jslm for the Prevention of Recurrent C difficile Infection
Carr A, Torres S, Kubiak D.
2024
Pharmacy Times
Fecal microbiota, live-jslm (RBL; REBYOTA™) for prevention of recurrent Clostridioides difficile infection: What Gastroenterology nurses need to know.
Cotto C, Baker K, Fallon E, Rimon S.
2024
Gastroenterology Nursing
Efficacy and safety of RBX2660 in patients after first recurrence of Clostridioides difficile infection – results from a phase 3, randomized ...
Feuerstadt P, Allegretti J, Tillotson GS, et al.
2024
Infect Dis Ther
PUNCH CD3-OLS: a phase 3 prospective observational cohort study to evaluate the safety and efficacy of fecal microbiota, live-jslm (REBYOTA) in adults with recurrent ...
Feuerstadt P, Chopra T, Knapple W, et al.
2024
Clinical Infectious Diseases
Fecal Microbiota, Live-jslm (RBL; REBYOTA™) for Recurrent Clostridioides difficile Infection. Journal for Nurse Practitioners
Garcia M, Castex J, Duhaime E, Monk M.
2024
Journal for Nurse Practitioners
Retrospective subgroup analysis of fecal microbiota, live-jslm (REBYOTA®) administered by colonoscopy under enforcement discretion for the prevention of ...
Knapple WL, Yoho DS, Sheh S, et al.
2024
Therap Adv Gastroenterol
Efficacy of fecal microbiota, live-jslm (Rebyota®) among patients exposed to non-C.difficile infection antibiotics: Post hoc subgroup analysis of a Phase 2 open label ...
Reveles KR, Gonzales-Luna AJ, Golan Y, et al.
2024
Open Forum Infectious Diseases
Bacteroides and related species: The keystone taxa of the human gut microbiota
Shin JH, Tillotson G, MacKenzie TN, et al.
2024
Anaerobe
RBX2660 (REBYOTA®) in preventing recurrence of Clostridioides difficile infection: a profile of its use in the USA
Blair HA.
2023
Drugs Ther Perspect
Role of the microbiome in essential metabolism in the human gut and its implications for Clostridioides difficile infection
Chopra T, Hylemon P, Tillotson G.
2023
Open Forum Infect Dis
The gut microbiota and microbiota-based therapies in Clostridioides difficile infection
Chopra T, Tillotson G, Hecht G.
2023
Front Med (Lausanne)
Final results from a phase II randomized, placebo-controlled clinical trial of RBX2660: a microbiota-based drug for the prevention of recurrent ...
Dubberke ER, Orenstein R, Khanna S, et al.
2023
Infect Dis Ther
Fecal microbiota, live-jslm for the prevention of recurrent Clostridioides difficile infection: subgroup analysis of PUNCH CD2 and PUNCH CD3
Feuerstadt P, Crawford C, Tan X, et al.
2023
J Clin Gastroenterol
Retrospective analysis of the safety and efficacy of fecal microbiota, Live-jslm (REBYOTA™️) administered under enforcement discretion to patients with ...
Feuerstadt P, Harvey A, Yoho DS, et al.
2023
Open Forum Infect Dis
Effect of fecal microbial transplantation on Clostridioides difficile infection: dysbiosis, metabolites and health related quality of life
Garey KW, Feuerstadt P, Dubberke ER, et al.
2023
Open Forum Infect Dis
Significant improvement in health-related quality of life with RBX2660: results from a phase 3 randomized, placebo-controlled trial in recurrent ...
Garey KW, Guo A, Harvey A, et al.
2023
Open Forum Infect Dis
Safety of investigational microbiota-based live biotherapeutic RBX2660 in individuals with recurrent C. difficile infection: Data from five prospective ...
Lee C, Louie T, Bancke L, et al.
2023
Therap Adv Gastroenterol
Budget impact analysis of fecal microbiota, live-jslm (FMBL) for preventing recurrent Clostridioides difficile infection in the US
Lodise T, Guo A, Yang M, et al.
2023
Adv Ther
Cost-effectiveness analysis of fecal microbiota, live-jslm (FMBL) for the prevention of recurrent Clostridioides difficile infection in the US
Lodise T, Guo A, Yang M, et al.
2023
Adv Ther
Two-year durability of REBYOTA™️ (RBL), a live biotherapeutic for the prevention of recurrent Clostridioides difficile infections
Orenstein R, Hecht G, Harvey A, et al.
2023
Open Forum Infect Dis
The role of microbiome-based therapeutics in Clostridioides difficile infection: durable, long-term results of RBX2660
Orenstein R.
2023
Infect Dis Ther
Human fecal bile acid analysis after investigational microbiota-based live biotherapeutic delivery for recurrent Clostridioides difficile infection
Papazyan R, Ferdyan N, Srinivasan K, et al.
2023
Microorganisms
Economic impact of recurrent Clostridioides difficile infection in the United States: a systematic literature review
Reveles K, Yang M, Garcia-Horton V, et al.
2023
Adv Ther
Microbiota-based live biotherapeutic RBX2660 for the reduction of recurrent Clostridioides difficile infection in patients with underlying comorbidities
Tillotson G, Feuerstadt P, Archbald-Pannone L, et al.
2023
Open Forum Infect Dis
The importance of a broad consortium of bacteria for a healthy gastrointestinal tract: a narrative review of the live biotherapeutic product REBYOTA
Tillotson G, Vedantam G, Shin JH, et al.
2023
Open Forum Infect Dis
Mortality, healthcare resource utilization, and cost among Medicare beneficiaries with Clostridioides difficile infection with and without sepsis
Amin A, Feuerstadt P, Nelson WW, et al.
2022
Ther Adv Infect Dis
Gut microbiome health and dysbiosis: a clinical primer
Bidell M, Hobbs A, Lodise T.
2022
Pharmacotherapy
Development and validation of a novel microbiome-based biomarker of post-antibiotic dysbiosis and subsequent restoration
Blount K, Jones C, Walsh D, et al.
2022
Front Microbiol
Mortality, healthcare, and costs of Clostridioides difficile infections and recurrences in medicare
Feuerstadt P, Nelson WW, Drozd EM, et al.
2022
J Am Med Dir Assoc
Clinical burden of recurrent Clostridioides difficile infection in the Medicare population: a real-world claims analysis
Feuerstadt P, Nelson WW, Tiegland C, et al.
2022
Antimicrob Steward Healthc Epidemiol
Efficacy and safety of RBX2660 in PUNCH CD3, a phase III, randomized, double-blind, placebo-controlled trial with a Bayesian primary analysis ...
Khanna S, Assi M, Lee C, et al.
2022
Drugs
Durable reduction of Clostridioides difficile infection recurrence and microbiome restoration after treatment with RBX2660: results from an open-label phase...
Orenstein R, Dubberke ER, Khanna S, et al.
2022
BMC Infect Dis
The role of the gut microbiome in colonization resistance and recurrent Clostridioides difficile infection
Seekatz A, Safdar N, Khanna S.
2022
Ther Adv Gastroenterol
Bacteroidetes: The Jekyll and Hyde of the human gut microbiome
Shin J, MacKenzie T, Tillotson GS.
2022
Pharm Times
The ins and outs of fecal microbiota transplantation administration
Tillotson G, LaPlante K, Feuerstadt P.
2022
Pharm Times
Efficacy and safety of a ready-to-drink bowel preparation for colonoscopy: a randomized, controlled, non-inferiority trial
Hookey L, Bertiger G, Lee Johnson K, et al.
2019
Therap Adv Gastroenterol
Results from a randomized, placebo-controlled clinical trial of a RBX2660-A microbiota-based drug for the prevention of recurrent Clostridium difficile ...
Dubberke ER, Lee CH, Orenstein R, et al.
2018
Clin Infect Dis
Safety and durability of RBX2660 (microbiota suspension) for recurrent Clostridium difficile infection: results of the PUNCH CD study
Orenstein R, Dubberke E, Hardi R, et al.
2016
Clin Infect Dis
Does the donor matter? Donor vs patient effects in the outcome of a next-generation microbiota-based drug trial for rCDI infection
Ray A, Jones C.
2016
Future Microbiol
A dual-action, low-volume bowel cleanser administered the day before colonoscopy: Results from the SEE CLEAR II study
Katz PO, Rex DK, EpsteinM, et al.
2013
Am J Gastroenterol
Efficacy and safety of a split-dose dual-action, low-volume bowel preparation for colonoscopy: The SEE CLEAR I study
Rex D, Katz P, Bertiger G, et al.
2013
J Crohns Colitis
Explore More
CONGRESSES
What congress material is available for this therapy area?